vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and Coeur Mining, Inc. (CDE). Click either name above to swap in a different company.

Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $674.8M, roughly 1.4× Coeur Mining, Inc.). Coeur Mining, Inc. runs the higher net margin — 31.9% vs 0.7%, a 31.2% gap on every dollar of revenue. On growth, Coeur Mining, Inc. posted the faster year-over-year revenue change (120.9% vs 42.9%). Coeur Mining, Inc. produced more free cash flow last quarter ($313.3M vs $-6.0M). Over the past eight quarters, Coeur Mining, Inc.'s revenue compounded faster (78.0% CAGR vs 53.3%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Coeur Mining, Inc. is a precious metals mining company listed on the New York Stock exchange. It operates five mines located in North America. Coeur employs 2,200 people and in 2012 it was the world's 9th largest silver producer. In 2013 the company changed its name to Coeur Mining, Inc. from Coeur d'Alene Mines and moved its head office to Chicago, Illinois from Coeur d'Alene, Idaho.

ASTH vs CDE — Head-to-Head

Bigger by revenue
ASTH
ASTH
1.4× larger
ASTH
$950.5M
$674.8M
CDE
Growing faster (revenue YoY)
CDE
CDE
+78.0% gap
CDE
120.9%
42.9%
ASTH
Higher net margin
CDE
CDE
31.2% more per $
CDE
31.9%
0.7%
ASTH
More free cash flow
CDE
CDE
$319.2M more FCF
CDE
$313.3M
$-6.0M
ASTH
Faster 2-yr revenue CAGR
CDE
CDE
Annualised
CDE
78.0%
53.3%
ASTH

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASTH
ASTH
CDE
CDE
Revenue
$950.5M
$674.8M
Net Profit
$6.6M
$215.0M
Gross Margin
Operating Margin
1.9%
48.6%
Net Margin
0.7%
31.9%
Revenue YoY
42.9%
120.9%
Net Profit YoY
184.4%
467.9%
EPS (diluted)
$0.12
$0.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
CDE
CDE
Q4 25
$950.5M
$674.8M
Q3 25
$956.0M
$554.6M
Q2 25
$654.8M
$480.6M
Q1 25
$620.4M
$360.1M
Q4 24
$665.2M
$305.4M
Q3 24
$478.7M
$313.5M
Q2 24
$486.3M
$222.0M
Q1 24
$404.4M
$213.1M
Net Profit
ASTH
ASTH
CDE
CDE
Q4 25
$6.6M
$215.0M
Q3 25
$373.0K
$266.8M
Q2 25
$9.4M
$70.7M
Q1 25
$6.7M
$33.4M
Q4 24
$-7.8M
$37.9M
Q3 24
$16.1M
$48.7M
Q2 24
$19.2M
$1.4M
Q1 24
$14.8M
$-29.1M
Operating Margin
ASTH
ASTH
CDE
CDE
Q4 25
1.9%
48.6%
Q3 25
2.0%
31.9%
Q2 25
3.1%
29.1%
Q1 25
3.3%
17.3%
Q4 24
0.1%
21.8%
Q3 24
5.9%
26.9%
Q2 24
6.2%
7.5%
Q1 24
7.5%
-1.6%
Net Margin
ASTH
ASTH
CDE
CDE
Q4 25
0.7%
31.9%
Q3 25
0.0%
48.1%
Q2 25
1.4%
14.7%
Q1 25
1.1%
9.3%
Q4 24
-1.2%
12.4%
Q3 24
3.4%
15.5%
Q2 24
3.9%
0.6%
Q1 24
3.7%
-13.7%
EPS (diluted)
ASTH
ASTH
CDE
CDE
Q4 25
$0.12
$0.37
Q3 25
$0.01
$0.41
Q2 25
$0.19
$0.11
Q1 25
$0.14
$0.06
Q4 24
$-0.14
$0.11
Q3 24
$0.33
$0.12
Q2 24
$0.40
$0.00
Q1 24
$0.31
$-0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
CDE
CDE
Cash + ST InvestmentsLiquidity on hand
$429.5M
$553.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
$3.3B
Total Assets
$2.2B
$4.7B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
CDE
CDE
Q4 25
$429.5M
$553.6M
Q3 25
$463.4M
$266.3M
Q2 25
$342.1M
$111.6M
Q1 25
$260.9M
$77.6M
Q4 24
$290.8M
$55.1M
Q3 24
$350.3M
$76.9M
Q2 24
$327.7M
$74.1M
Q1 24
$337.3M
$67.5M
Stockholders' Equity
ASTH
ASTH
CDE
CDE
Q4 25
$779.3M
$3.3B
Q3 25
$775.5M
$3.1B
Q2 25
$765.5M
$2.8B
Q1 25
$745.4M
$2.7B
Q4 24
$712.7M
$1.1B
Q3 24
$704.6M
$1.1B
Q2 24
$678.9M
$1.0B
Q1 24
$653.5M
$1.0B
Total Assets
ASTH
ASTH
CDE
CDE
Q4 25
$2.2B
$4.7B
Q3 25
$2.2B
$4.5B
Q2 25
$1.4B
$4.2B
Q1 25
$1.3B
$4.1B
Q4 24
$1.4B
$2.3B
Q3 24
$1.3B
$2.2B
Q2 24
$1.3B
$2.1B
Q1 24
$1.2B
$2.1B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
CDE
CDE
Operating Cash FlowLast quarter
$-2.9M
$374.6M
Free Cash FlowOCF − Capex
$-6.0M
$313.3M
FCF MarginFCF / Revenue
-0.6%
46.4%
Capex IntensityCapex / Revenue
0.3%
9.1%
Cash ConversionOCF / Net Profit
-0.44×
1.74×
TTM Free Cash FlowTrailing 4 quarters
$104.5M
$665.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
CDE
CDE
Q4 25
$-2.9M
$374.6M
Q3 25
$10.0M
$237.7M
Q2 25
$90.9M
$207.0M
Q1 25
$16.6M
$67.6M
Q4 24
$-10.9M
$63.8M
Q3 24
$34.0M
$111.1M
Q2 24
$23.2M
$15.2M
Q1 24
$6.0M
$-15.9M
Free Cash Flow
ASTH
ASTH
CDE
CDE
Q4 25
$-6.0M
$313.3M
Q3 25
$7.4M
$188.7M
Q2 25
$89.5M
$146.1M
Q1 25
$13.6M
$17.6M
Q4 24
$-13.5M
$16.1M
Q3 24
$31.7M
$69.1M
Q2 24
$20.4M
$-36.2M
Q1 24
$5.6M
$-58.0M
FCF Margin
ASTH
ASTH
CDE
CDE
Q4 25
-0.6%
46.4%
Q3 25
0.8%
34.0%
Q2 25
13.7%
30.4%
Q1 25
2.2%
4.9%
Q4 24
-2.0%
5.3%
Q3 24
6.6%
22.0%
Q2 24
4.2%
-16.3%
Q1 24
1.4%
-27.2%
Capex Intensity
ASTH
ASTH
CDE
CDE
Q4 25
0.3%
9.1%
Q3 25
0.3%
8.8%
Q2 25
0.2%
12.7%
Q1 25
0.5%
13.9%
Q4 24
0.4%
15.6%
Q3 24
0.5%
13.4%
Q2 24
0.6%
23.2%
Q1 24
0.1%
19.8%
Cash Conversion
ASTH
ASTH
CDE
CDE
Q4 25
-0.44×
1.74×
Q3 25
26.69×
0.89×
Q2 25
9.65×
2.93×
Q1 25
2.48×
2.03×
Q4 24
1.69×
Q3 24
2.11×
2.28×
Q2 24
1.21×
10.69×
Q1 24
0.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

CDE
CDE

Segment breakdown not available.

Related Comparisons